Cargando…

Neutralizing Monoclonal Antibodies Reduce Human Cytomegalovirus Infection and Spread in Developing Placentas

Congenital human cytomegalovirus (HCMV) infection is a leading cause of birth defects worldwide, yet the most effective strategies for preventing virus transmission during pregnancy are unknown. We measured the efficacy of human monoclonal antibodies (mAbs) to HCMV attachment/entry factors glycoprot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tabata, Takako, Petitt, Matthew, Fang-Hoover, June, Freed, Daniel C., Li, Fengsheng, An, Zhiqiang, Wang, Dai, Fu, Tong-Ming, Pereira, Lenore
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963214/ https://www.ncbi.nlm.nih.gov/pubmed/31569508 http://dx.doi.org/10.3390/vaccines7040135

Ejemplares similares

HCMV Infection of Human Trophoblast Progenitor Cells of the Placenta Is Neutralized by a Human Monoclonal Antibody to Glycoprotein B and Not by Antibodies to the Pentamer Complex
por: Zydek, Martin, et al.
Publicado: (2014)

Neutralizing Antibodies to Human Cytomegalovirus Recombinant Proteins Reduce Infection in an Ex Vivo Model of Developing Human Placentas
por: Tabata, Takako, et al.
Publicado: (2022)

A conditionally replication-defective cytomegalovirus vaccine elicits potent and diverse functional monoclonal antibodies in a phase I clinical trial
por: Li, Leike, et al.
Publicado: (2021)

Neutralization Epitopes in Trimer and Pentamer Complexes Recognized by Potent Cytomegalovirus-Neutralizing Human Monoclonal Antibodies
por: Ai, Yuanbao, et al.
Publicado: (2022)

Complement enhances in vitro neutralizing potency of antibodies to human cytomegalovirus glycoprotein B (gB) and immune sera induced by gB/MF59 vaccination
por: Li, Fengsheng, et al.
Publicado: (2017)

Neutralizing Antibodies Limit Cell-Associated Spread of Human Cytomegalovirus in Epithelial Cells and Fibroblasts
por: Reuter, Nina, et al.
Publicado: (2022)

Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral gH/gL/pUL128-131 Pentameric Complex
por: Ha, Sha, et al.
Publicado: (2017)

Structural basis for HCMV Pentamer recognition by neuropilin 2 and neutralizing antibodies
por: Wrapp, Daniel, et al.
Publicado: (2022)

Generation of potent neutralizing human monoclonal antibodies against cytomegalovirus infection from immune B cells
por: Funaro, Ada, et al.
Publicado: (2008)

Potent Bispecific Neutralizing Antibody Targeting Glycoprotein B and the gH/gL/pUL128/130/131 Complex of Human Cytomegalovirus
por: Su, Hang, et al.
Publicado: (2021)

Recognition of a highly conserved glycoprotein B epitope by a bivalent antibody neutralizing HCMV at a post-attachment step
por: Ye, Xiaohua, et al.
Publicado: (2020)

Vaccination with a replication-defective cytomegalovirus vaccine elicits a glycoprotein B-specific monoclonal antibody repertoire distinct from natural infection
por: Valencia, Sarah M., et al.
Publicado: (2023)

A fully human neutralizing monoclonal antibody targeting a highly conserved epitope of the human cytomegalovirus glycoprotein B
por: Okamoto, Miwa, et al.
Publicado: (2023)

Comparative neutralizing potencies of antibodies suggest conservation as well as mechanistic differences in human cytomegalovirus entry into epithelial and endothelial cells
por: Qi, Ying, et al.
Publicado: (2020)

Polymorphic Forms of Human Cytomegalovirus Glycoprotein O Protect against Neutralization of Fibroblast Entry by Antibodies Targeting Epitopes Defined by Glycoproteins H and L
por: He, Li, et al.
Publicado: (2022)

Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus
por: Bootz, Anna, et al.
Publicado: (2017)

Functionally inactivated dominant viral antigens of human cytomegalovirus delivered in replication incompetent adenovirus type 6 vectors as vaccine candidates
por: Tang, Aimin, et al.
Publicado: (2017)

Pathogenesis of Preeclampsia and Therapeutic Approaches Targeting the Placenta
por: Jena, Manoj Kumar, et al.
Publicado: (2020)

Neutralizing monoclonal antibodies for treatment of COVID-19
por: Taylor, Peter C., et al.
Publicado: (2021)

Tackling COVID-19 with neutralizing monoclonal antibodies
por: Corti, Davide, et al.
Publicado: (2021)

Broadly neutralizing monoclonal antibodies for HIV prevention
por: Miner, Maurine D., et al.
Publicado: (2021)

Tackling COVID-19 with neutralizing monoclonal antibodies
por: Corti, Davide, et al.
Publicado: (2021)

Association of human cytomegalovirus (HCMV) neutralizing antibodies with antibodies to the HCMV glycoprotein complexes
por: Shibamura, Miho, et al.
Publicado: (2020)

A neutralizing-protective supersite of human monoclonal antibodies for yellow fever virus
por: Li, Yan, et al.
Publicado: (2022)

Humanization and Characterization of an Anti-Ricin Neutralization Monoclonal Antibody
por: Hu, Wei-Gang, et al.
Publicado: (2012)

An in vitro methodology for discovering broadly-neutralizing monoclonal antibodies
por: Ahmadi, Shirin, et al.
Publicado: (2020)

Neutralizing monoclonal antibodies for COVID-19 treatment and prevention
por: Jaworski, Juan Pablo
Publicado: (2021)

Neutralizing monoclonal antibodies against highly pathogenic coronaviruses
por: Xiang, Rong, et al.
Publicado: (2022)

Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies
por: McCoy, Laura E., et al.
Publicado: (2015)

Glycoprotein N of Human Cytomegalovirus Protects the Virus from Neutralizing Antibodies
por: Kropff, Barbara, et al.
Publicado: (2012)

Structural Basis of HCV Neutralization by Human Monoclonal Antibodies Resistant to Viral Neutralization Escape
por: Krey, Thomas, et al.
Publicado: (2013)

Potent neutralizing monoclonal antibodies against Ebola virus infection
por: Zhang, Qi, et al.
Publicado: (2016)

Pharmacokinetics and Immunogenicity of Broadly Neutralizing HIV Monoclonal Antibodies in Macaques
por: Rosenberg, Yvonne, et al.
Publicado: (2015)

Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success
por: Jaworski, Juan Pablo, et al.
Publicado: (2017)

Broad neutralization of SARS-related viruses by human monoclonal antibodies
por: Wec, Anna Z., et al.
Publicado: (2020)

Immunotherapy of SARS based on combinations of neutralizing human monoclonal antibodies
por: Du, Lanying, et al.
Publicado: (2010)

A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19
Publicado: (2020)

Novel neutralizing human monoclonal antibodies against tetanus neurotoxin
por: Minamitani, Takeharu, et al.
Publicado: (2021)

Neutralizing Monoclonal Antibody Use and COVID-19 Infection Outcomes
por: Ambrose, Nalini, et al.
Publicado: (2023)

Targeting Human-Cytomegalovirus-Infected Cells by Redirecting T Cells Using an Anti-CD3/Anti-Glycoprotein B Bispecific Antibody
por: Meng, Weixu, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1h3brisnmagt7ngashn8uaqm6t